Display options
Cite
Assi HA, Hornbacker K, Shaheen S, et al. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021;50(6):890-894doi: 10.1097/MPA.0000000000001841.
Assi, H. A., Hornbacker, K., Shaheen, S., Wittenberg, T., Silberman, R., & Kunz, P. L. (2021). Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas, 50(6), 890-894. https://doi.org/10.1097/MPA.0000000000001841
Assi, Hussein A, et al. "Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors." Pancreas vol. 50,6 (2021): 890-894. doi: https://doi.org/10.1097/MPA.0000000000001841
Assi HA, Hornbacker K, Shaheen S, Wittenberg T, Silberman R, Kunz PL. Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors. Pancreas. 2021 Jul 01;50(6):890-894. doi: 10.1097/MPA.0000000000001841. PMID: 34398071.
Copy Download .nbib Format: NLM
Share it on

Pancreas. 2021 Jul 01;50(6):890-894. doi: 10.1097/MPA.0000000000001841.

Rapid Progression After 177Lu-DOTATATE in Patients With Neuroendocrine Tumors.

Pancreas

Hussein A Assi, Kathleen Hornbacker, Shagufta Shaheen, Theresa Wittenberg, Robyn Silberman, Pamela L Kunz

Affiliations

  1. From the Section of Hematology/Oncology, Department of Medicine, Boston University School of Medicine, Boston, MA.
  2. Section of Medical Oncology, Department of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT.

PMID: 34398071 DOI: 10.1097/MPA.0000000000001841

Abstract

ABSTRACT: Peptide receptor radionuclide therapy (PRRT) is a treatment option for somatostatin receptor-positive, unresectable or metastatic neuroendocrine tumors (NETs). Despite high disease control rates seen with PRRT, a subset of the NET population seems to have a short progression-free interval. We hypothesize that patients with NETs with rapid progression post-PRRT may have mixed low- and high-grade cell populations, and PRRT treats the lower-grade component, allowing the more aggressive high-grade component to progress.We report 7 patients with biopsy-proven NET who received PRRT with 177Lu-DOTATATE at the Stanford Cancer Center who had evidence of progressive disease (PD) on or within 6 months of therapy.All patients had primary pancreatic, metastatic, well-differentiated NET on diagnosis and were heavily pretreated before receiving PRRT. Two patients had PD while on PRRT; 5 had PD within 6 months of completing PRRT. The median time from the last cycle to PD was 3.2 months (range, 1.1-4.6 months). The median progression-free survival was 7.7 months (95% confidence interval, 5.7-9.8 months). Three patients had a repeat biopsy post-PRRT, 2 of which demonstrated higher disease grade compared with their initial pathology. Further evaluation in larger patient cohorts is warranted to elucidate predictive factors of PRRT response/nonresponse to enable better patient selection.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Conflict of interest statement

P.L.K. receives research funding from Advanced Accelerator Applications, Brahms, Ipsen, Lexicon Pharmaceuticals, and Xencor. She has served on advisory boards for Advanced Accelerator Applications and

References

  1. Sackstein PE, O'Neil DS, Neugut AI, et al. Epidemiologic trends in neuroendocrine tumors: an examination of incidence rates and survival of specific patient subgroups over the past 20 years. Semin Oncol. 2018;45:249–258. - PubMed
  2. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol. 2017;3:1335–1342. - PubMed
  3. Taal BG, Visser O. Epidemiology of neuroendocrine tumours. Neuroendocrinology. 2004;80(suppl 1):3–7. - PubMed
  4. Brabander T, van der Zwan WA, Teunissen JJM, et al. Long-term efficacy, survival, and safety of [177Lu-DOTA0,Tyr3]octreotate in patients with gastroenteropancreatic and bronchial neuroendocrine tumors. Clin Cancer Res. 2017;23:4617–4624. - PubMed
  5. Strosberg J, El-Haddad G, Wolin E, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–135. - PubMed
  6. Strosberg J, Wolin E, Chasen B, et al. Overall survival, progression-free survival, and quality of life updates from the NETTER-1 study: 177Lu-Dotatate vs. high dose octreotide in progressive midgut neuroendocrine tumors. Neuroendocrinology. 2018;106(suppl 1):260.abstract K22. - PubMed
  7. Advanced Accelerator Applications USA, Inc. LUTATHERA® [package insert]. July 2018. Available at: https://hcp.lutathera.com/wp-content/uploads/2019/09/LUTATHERA_lutetium_Lu_177_dotatate_FDA_Prescribing_Information.pdf. Accessed January 2, 2020. - PubMed
  8. Ezziddin S, Khalaf F, Vanezi M, et al. Outcome of peptide receptor radionuclide therapy with 177Lu-octreotate in advanced grade 1/2 pancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2014;41:925–933. - PubMed
  9. Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130. - PubMed
  10. Ezziddin S, Attassi M, Yong-Hing CJ, et al. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate. J Nucl Med. 2014;55:183–190. - PubMed
  11. Sansovini M, Severi S, Ianniello A, et al. Long-term follow-up and role of FDG PET in advanced pancreatic neuroendocrine patients treated with (177)Lu-D OTATATE. Eur J Nucl Med Mol Imaging. 2017;44:490–499. - PubMed
  12. Kong G, Thompson M, Collins M, et al. Assessment of predictors of response and long-term survival of patients with neuroendocrine tumour treated with peptide receptor chemoradionuclide therapy (PRCRT). Eur J Nucl Med Mol Imaging. 2014;41:1831–1844. - PubMed
  13. Waseem N, Aparici CM, Kunz PL. Evaluating the role of theranostics in grade 3 neuroendocrine neoplasms. J Nucl Med. 2019;60:882–891. - PubMed
  14. Ezziddin S, Sabet A, Heinemann F, et al. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate. J Nucl Med. 2011;52:1197–1203. - PubMed
  15. Merola E, Prasad V, Pascher A, et al. Peritoneal carcinomatosis in gastro-entero-pancreatic neuroendocrine neoplasms: clinical impact and effectiveness of the available therapeutic options. Neuroendocrinology. 2020;110:517–524. - PubMed
  16. Werner RA, Lapa C, Ilhan H, et al. Survival prediction in patients undergoing radionuclide therapy based on intratumoral somatostatin-receptor heterogeneity. Oncotarget. 2017;8:7039–7049. - PubMed
  17. Werner RA, Ilhan H, Lehner S, et al. Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy. Mol Imaging Biol. 2019;21:582–590. - PubMed
  18. Bodei L, Kidd M, Modlin IM, et al. Measurement of circulating transcripts and gene cluster analysis predicts and defines therapeutic efficacy of peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2016;43:839–851. - PubMed
  19. Bodei L, Kidd MS, Singh A, et al. PRRT genomic signature in blood for prediction of 177Lu-octreotate efficacy. Eur J Nucl Med Mol Imaging. 2018;45:1155–1169. - PubMed
  20. Wetz C, Apostolova I, Steffen IG, et al. Predictive value of asphericity in pretherapeutic [111In]DTPA-octreotide SPECT/CT for response to peptide receptor radionuclide therapy with [177Lu]DOTATATE. Mol Imaging Biol. 2017;19:437–445. - PubMed
  21. de Mestier L, Armani M, Cros J, et al. Lesion-by-lesion correlation between uptake at FDG PET and the Ki67 proliferation index in resected pancreatic neuroendocrine tumors. Dig Liver Dis. 2019;51:1720–1724. - PubMed
  22. Graf J, Pape UF, Jann H, et al. Prognostic significance of somatostatin receptor heterogeneity in progressive neuroendocrine tumor treated with Lu-177 DOTATOC or Lu-177 DOTATATE. Eur J Nucl Med Mol Imaging. 2020;47:881–894. - PubMed

Publication Types